Hansoh Pharmaceutical Rises Nearly 4% as HS-20105 Receives Clinical Trial Approval for Advanced Solid Tumors

　　Hansoh Pharma(03692) rose 3.78% at midday, currently trading at HKD 10.42, with a turnover of HKD 56.95425 million.

Hansoh Pharma announced yesterday that "HS-20105," a Class 1 therapeutic biological product independently developed by its subsidiaries, Shanghai Hansoh Biomedical Technology Co., Ltd. and Changzhou Hengbang Pharmaceutical Co., Ltd., has received the clinical trial notification issued by the National Medical Products Administration. It is intended for the treatment of advanced solid tumors, with specific indications to be determined after clinical trials.

Editor: Lu Yujun